Hutchmed (HCM) said Wednesday a phase 2 study of a combination therapy it co-developed with AstraZeneca (AZN) showed clinically meaningful and durable objective response rates in patients with a type of non-small cell lung cancer.
The study showed that the safety and tolerability of the combination of Tagrisso and Orpathys, co-developed by AstraZeneca and Hutchmed, was consistent with the known safety profiles of the combination, with no new safety signals identified, Hutchmed said.
Price: 18.81, Change: +0.01, Percent Change: +0.05
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。